PubRank

Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer

Clinical Trial ID NCT01420965

PubWeight™ 24.42‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01420965

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010 12.60
2 A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989 7.01
3 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
4 Carcinoma of the prostate. N Engl J Med 1991 2.47
5 Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012 1.33
6 Molecular pathways and targets in prostate cancer. Oncotarget 2014 1.00
7 Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014 0.99
8 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
9 Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol 2014 0.92
10 AR function in promoting metastatic prostate cancer. Cancer Metastasis Rev 2014 0.91
11 Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene 2013 0.91
12 Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 2014 0.90
13 Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. Ther Adv Vaccines 2014 0.86
14 Optimizing dendritic cell-based approaches for cancer immunotherapy. Yale J Biol Med 2014 0.85
15 Immunotherapy for solid tumors--a review for surgeons. J Surg Res 2013 0.83
16 Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Cancer Immunol Immunother 2015 0.82
17 Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. Front Immunol 2015 0.82
18 Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy. Core Evid 2014 0.81
19 Immune response to sipuleucel-T in prostate cancer. Cancers (Basel) 2012 0.79
20 A primer on tumour immunology and prostate cancer immunotherapy. Can Urol Assoc J 2016 0.79
21 Beyond sipuleucel-T: immune approaches to treating prostate cancer. Curr Treat Options Oncol 2014 0.79
22 Immunotherapy for prostate cancer: False promises or true hope? Cancer 2016 0.78
23 Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. J Natl Compr Canc Netw 2013 0.77
24 The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer. Rev Urol 2014 0.77
25 A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial. J Immunother Cancer 2015 0.76
26 Immune Therapy for Prostate Cancer. Cancer J 2016 0.76
27 Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? Oncol Rev 2016 0.76
28 Evaluating immune responses after sipuleucel-T therapy. Cancer Biol Ther 2015 0.75
29 A Perspective of Immunotherapy for Prostate Cancer. Cancers (Basel) 2016 0.75
Next 100